Eloralintide And Tirzepatide
EloraTZP
Sources
registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07881432
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2115. Conditions Obesity. The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 y
ClinicalTrials.gov NCT07881432 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07881458
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1000. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last abo
ClinicalTrials.gov NCT07881458 protocol and results modules
registry, as of 2026-01-30Stale
https://clinicaltrials.gov/study/NCT06916065
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 188. Conditions Overweight; Obesity. The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be
ClinicalTrials.gov NCT06916065 protocol and results modules